Loading
EyePoint, Inc. Stock: price and insider trades · United States
1 insider bought €45k of shares over the last 90 days, the latest by Zaderej Karen L., filed 18 Aug 2026.
EyePoint, Inc.: what insiders have been doing
Every trade that managers of EyePoint, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. From 23 October 2025 to 23 October 2026, the disclosure feed for EyePoint, Inc. logged 46 filings by 7 insiders.
The record shows 2 purchases on the open market worth €62k, made by 2 insiders, against 9 sales worth €1.7M by 3 insiders. On balance, insiders were net sellers of €1.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 senior executive and 1 chief executive. Cormorant Asset Management, LP filed the largest sale, €808k, on 8 December 2025.
Compared with its exchange (3,167 companies, median 24 filings), a count of 46 filings is above the norm. Since 2016, the database holds 49 purchases and 62 sales by insiders of the company. The 10-K for the year ended 31 December 2025 shows 31.4 m USD of revenue and -232.0 m USD of net income.
The latest purchase dates back some time: it was published 67 days ago, on 18 August 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
373
Thresholds
n/a
Buy Volume
€109M
49 ops. · all time
Sell Volume
€75M
62 ops. · all time
Who traded when
BuySaleKaren L. Zaderej5 buys
Ramiro Ribeiro5 sales
Lurker Nancy3 sales
Cormorant Asset Management, LP1 sale
Jay S. Duker1 buy
Since the insiders bought
- -38.9%Entry US$6.30 · Close at T+30 US$3.85
- -13.1%Entry US$13.90 · Close at T+90 US$12.08
- +78.2%Entry US$7.99 · Close at T+365 US$14.24
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate EyePoint, Inc. Hold (neutral), based on 8 analysts. Average price target: US$8.44.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$0.43
Analyst consensus
8 analystsHold
US$0.50Target US$8.44(+1862%)US$31.00
Income statement
RevenueUS$31.4M
Gross profitUS$29.3M93% margin
EBITDA-US$229.3M-731% margin
Net income-US$232M-739.4% margin
Valuation
PER (forward)-0.2x
P/Book0.2x
Beta1.68
Balance sheet & cash
Market capUS$36.1M
Total debtUS$20.8M
Free Cash Flow-US$243.4M
Debt / Equity13%
Profitability & ownership
ROE-148.7%
ROA-74.9%
% insiders3.5%
% institutions117.0%
Last declaration on 24 August 2026
Declarations373 total
5,000 shares0Common StockSEC:0001429932-26-000010:0
64,953 shares0Common StockSEC:0001429932-26-000010:3
5,000 shares0Common StockSEC:0001429932-26-000010:1
64,953 shares0Common StockSEC:0001429932-26-000010:2
10,600 shares@ US$4.930.016% mcap100.0% of flowCommon StockSEC:0001530968-26-000004:0
Canonical exit: 16 Nov 2026 (T+90)
1,235 shares@ US$12.80970.0050% mcap0.3% of flowCommonSEC144:0001959173-26-005318
421,235 shares@ US$13.051.74% mcap99.7% of flowCommonSEC144:0001959173-26-005309
16,667 shares0Common StockSEC:0001630864-26-000010:0
8,059 shares@ US$14.720.037% mcap10.5% of flowCommon StockSEC:0001630864-26-000010:1
3,627 shares@ US$12.93100.0% of flowCommon StockSEC:0001429932-26-000008:1
7,500 shares0Common StockSEC:0001429932-26-000008:0
2,437 shares@ US$8.260.0038% mcap5.9% of flowCommon StockSEC:0002013623-26-000010:0
2,437 shares@ US$15.000.0069% mcap10.7% of flowCommon StockSEC:0002013623-26-000010:1
76,766 shares@ US$13.1187.8% of flowCommon StockSEC:0001630864-26-000008:0
1,500 shares@ US$13.14921.7% of flowCommon StockSEC:0001630864-26-000006:0
Canonical exit: 14 Jun 2026 (T+90)
5,000 shares0Common StockSEC:0001429932-26-000006:1
5,000 shares0Common StockSEC:0001429932-26-000006:0
2,438 shares@ US$17.87Common StockSEC:0002013623-26-000008:1
2,438 shares@ US$8.266.0% of flowCommon StockSEC:0002013623-26-000008:0
2,437 shares@ US$15.00Common StockSEC:0002013623-26-000006:1
2,437 shares@ US$8.265.9% of flowCommon StockSEC:0002013623-26-000006:0
10,054 shares@ US$16.86Common StockSEC:0001630864-26-000004:1
42,544 shares@ US$17.10Common StockSEC:0002013623-26-000004:1
4,487 shares@ US$16.86Common StockSEC:0001429932-26-000004:1
15,285 shares0Common StockSEC:0001429932-26-000004:0
25 of 373 declarations
About EyePoint, Inc.
EyePoint, Inc. is a company focused on developing innovative ophthalmic treatments. It concentrates on solutions for serious eye diseases.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
